<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33860461</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>03</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-7479</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics</Title><ISOAbbreviation>Neurotherapeutics</ISOAbbreviation></Journal><ArticleTitle>Reconditioning the Neurogenic Niche of Adult Non-human Primates by Antisense Oligonucleotide-Mediated Attenuation of TGF&#x3b2; Signaling.</ArticleTitle><Pagination><StartPage>1963</StartPage><EndPage>1979</EndPage><MedlinePgn>1963-1979</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s13311-021-01045-2</ELocationID><Abstract><AbstractText>Adult neurogenesis is a target for brain rejuvenation as well as regeneration in aging and disease. Numerous approaches showed efficacy to elevate neurogenesis in rodents, yet translation into therapies has not been achieved. Here, we introduce a novel human TGF&#x3b2;-RII (Transforming Growth Factor-Receptor Type II) specific LNA-antisense oligonucleotide ("locked nucleotide acid"-"NVP-13"), which reduces TGF&#x3b2;-RII expression and downstream receptor signaling in human neuronal precursor cells (ReNcell CX&#xae; cells) in vitro. After we injected cynomolgus non-human primates repeatedly i.th. with NVP-13 in a preclinical regulatory 13-week GLP-toxicity program, we could specifically downregulate TGF&#x3b2;-RII mRNA and protein in vivo. Subsequently, we observed a dose-dependent upregulation of the neurogenic niche activity within the hippocampus and subventricular zone: human neural progenitor cells showed significantly (up to threefold over control) enhanced differentiation and cell numbers. NVP-13 treatment modulated canonical and non-canonical TGF&#x3b2; pathways, such as MAPK and PI3K, as well as key transcription factors and epigenetic factors involved in stem cell maintenance, such as MEF2A and pFoxO3. The latter are also dysregulated in clinical neurodegeneration, such as amyotrophic lateral sclerosis. Here, we provide for the first time in vitro and in vivo evidence for a novel translatable approach to treat neurodegenerative disorders by modulating neurogenesis.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Peters</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospital Regensburg, Regensburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Velvio GmbH, Am Biopark 11, Regensburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuespert</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospital Regensburg, Regensburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Velvio GmbH, Am Biopark 11, Regensburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wirkert</LastName><ForeName>Eva</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospital Regensburg, Regensburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Velvio GmbH, Am Biopark 11, Regensburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heydn</LastName><ForeName>Rosmarie</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospital Regensburg, Regensburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Velvio GmbH, Am Biopark 11, Regensburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jurek</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Institute for Molecular and Cellular Anatomy, University of Regensburg, Regensburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johannesen</LastName><ForeName>Siw</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospital Regensburg, Regensburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Velvio GmbH, Am Biopark 11, Regensburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsam</LastName><ForeName>Ohnmar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospital Regensburg, Regensburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Korte</LastName><ForeName>Sven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Covance Preclinical Services GmbH, Muenster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ludwig</LastName><ForeName>Florian Timo</ForeName><Initials>FT</Initials><AffiliationInfo><Affiliation>Covance Preclinical Services GmbH, Muenster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mecklenburg</LastName><ForeName>Lars</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Covance Preclinical Services GmbH, Muenster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mrowetz</LastName><ForeName>Heike</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institute of Molecular Regenerative Medicine, Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Paracelsus Medical University Salzburg, Salzburg, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Experimental and Clinical Cell Therapy, Spinal Cord Injury and Tissue Regeneration Center (SCI-TReCS), Paracelsus Medical University Salzburg, Salzburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Altendorfer</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Institute of Molecular Regenerative Medicine, Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Paracelsus Medical University Salzburg, Salzburg, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Experimental and Clinical Cell Therapy, Spinal Cord Injury and Tissue Regeneration Center (SCI-TReCS), Paracelsus Medical University Salzburg, Salzburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poupardin</LastName><ForeName>Rodolphe</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute of Experimental and Clinical Cell Therapy, Spinal Cord Injury and Tissue Regeneration Center (SCI-TReCS), Paracelsus Medical University Salzburg, Salzburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petri</LastName><ForeName>Susanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospital MHH, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thal</LastName><ForeName>Dietmar R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Department for Imaging and Pathology, Laboratory for Neuropathology, University of Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Neuropathology, Institute of Pathology, Ulm University, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hermann</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Translational Neurodegeneration Section "Albrecht-Kossel", Department of Neurology, University Medical Center Rostock, University of Rostock, and German Center for Neurodegenerative Diseases (DZNE) Rostock, Rostock, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weishaupt</LastName><ForeName>Jochen H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospital Mannheim, Mannheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weis</LastName><ForeName>Joachim</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Neuropathology, RWTH Aachen University Medical School, Aachen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aksoylu</LastName><ForeName>Inci Sevval</ForeName><Initials>IS</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institute, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lewandowski</LastName><ForeName>Sebastian A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institute, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>SciLifeLab, School of Biotechnology, Royal Institute of Technology, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aigner</LastName><ForeName>Ludwig</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute of Molecular Regenerative Medicine, Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Paracelsus Medical University Salzburg, Salzburg, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Experimental and Clinical Cell Therapy, Spinal Cord Injury and Tissue Regeneration Center (SCI-TReCS), Paracelsus Medical University Salzburg, Salzburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bruun</LastName><ForeName>Tim-Henrik</ForeName><Initials>TH</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospital Regensburg, Regensburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Velvio GmbH, Am Biopark 11, Regensburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bogdahn</LastName><ForeName>Ulrich</ForeName><Initials>U</Initials><Identifier Source="ORCID">0000-0003-0826-7482</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University Hospital Regensburg, Regensburg, Germany. uli.bogdahn@ukr.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Velvio GmbH, Am Biopark 11, Regensburg, Germany. uli.bogdahn@ukr.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Molecular Regenerative Medicine, Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Paracelsus Medical University Salzburg, Salzburg, Austria. uli.bogdahn@ukr.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurotherapeutics</MedlineTA><NlmUniqueID>101290381</NlmUniqueID><ISSNLinking>1878-7479</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016376">Oligonucleotides, Antisense</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016212">Transforming Growth Factor beta</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008252" MajorTopicYN="N">Macaca fascicularis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058953" MajorTopicYN="N">Neural Stem Cells</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055495" MajorTopicYN="N">Neurogenesis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016376" MajorTopicYN="N">Oligonucleotides, Antisense</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011323" MajorTopicYN="N">Primates</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016212" MajorTopicYN="N">Transforming Growth Factor beta</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>UB and LA are partners at NeuroVision Pharma GmbH, which holds intellectual property on TGF-beta receptor modulators. Lars Mecklenburg, Florian Ludwig, and Sven Korte are active employers of Covance, who performed the GLP-Tox-Study. DRT received speaker honorary or travel reimbursement from Novartis Pharma AG (Switzerland), GE Healthcare (UK), and UCB (Belgium) and collaborated with Novartis Pharma AG (Switzerland), Probiodrug (Germany), GE-Healthcare (UK), and Janssen Pharmaceutical Companies (Belgium). All the other authors declare that they do not have any conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>3</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>48</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33860461</ArticleId><ArticleId IdType="pmc">PMC8609055</ArticleId><ArticleId IdType="doi">10.1007/s13311-021-01045-2</ArticleId><ArticleId IdType="pii">10.1007/s13311-021-01045-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Altman J. Are New Neurons Formed in the Brains of Adult Mammals? Science New York, N.Y. 1962;135(3509):1127&#x2013;1128.</Citation><ArticleIdList><ArticleId IdType="pubmed">13860748</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksson PS, Perfilieva E, Bj&#xf6;rk-Eriksson T, et al. Neurogenesis in the adult human hippocampus. Nature medicine. 1998;4(11):1313&#x2013;1317.</Citation><ArticleIdList><ArticleId IdType="pubmed">9809557</ArticleId></ArticleIdList></Reference><Reference><Citation>Gould E. How widespread is adult neurogenesis in mammals? Nature Reviews Neuroscience. 2007;8(6):481&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pubmed">17514200</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao C, Deng W, Gage FH. Mechanisms and Functional Implications of Adult Neurogenesis. Cell. 2008;132(4):645&#x2013;660.</Citation><ArticleIdList><ArticleId IdType="pubmed">18295581</ArticleId></ArticleIdList></Reference><Reference><Citation>St John W. Neurogenesis of patterns of automatic ventilatory activity. Progress in Neurobiology. 1998;56(1):97&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">9723132</ArticleId></ArticleIdList></Reference><Reference><Citation>Magavi SS, Leavitt BR, Macklis JD. Induction of neurogenesis in the neocortex of adult mice. Nature. 2000;405(6789):951&#x2013;955.</Citation><ArticleIdList><ArticleId IdType="pubmed">10879536</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernier PJ, B&#xe9;dard A, Vinet J, L&#xe9;vesque M, Parent A. Newly generated neurons in the amygdala and adjoining cortex of adult primates. Proc. Natl. Acad. Sci. U.S.A. 2002;99(17):11464&#x2013;11469.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC123279</ArticleId><ArticleId IdType="pubmed">12177450</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao M, Momma S, Delfani K, et al. Evidence for neurogenesis in the adult mammalian substantia nigra. Proc. Natl. Acad. Sci. U.S.A. 2003;100(13):7925&#x2013;7930.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC164689</ArticleId><ArticleId IdType="pubmed">12792021</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermann A, Maisel M, Suess C, et al. Functional neurogenesis in the adult midbrain? Aktuelle Neurologie. 33(S 1), P275 (2006).</Citation></Reference><Reference><Citation>Lojewski X, Hermann A, cells FWS, 2014. Human adult white matter progenitor cells are multipotent neuroprogenitors similar to adult hippocampal progenitors. Wiley Online Library</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3973711</ArticleId><ArticleId IdType="pubmed">24558163</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, Magavi SSP, Macklis JD. Neurogenesis of corticospinal motor neurons extending spinal projections in adult mice. Proc. Natl. Acad. Sci. U.S.A. 2004;101(46):16357&#x2013;16362.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC528970</ArticleId><ArticleId IdType="pubmed">15534207</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto S-I, Yamamoto N, Kitamura T, Nakamura K, Nakafuku M. Proliferation of Parenchymal Neural Progenitors in Response to Injury in the Adult Rat Spinal Cord. Experimental Neurology. 2001;172(1):115&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pubmed">11681845</ArticleId></ArticleIdList></Reference><Reference><Citation>Vessal M, Aycock A, Garton MT, Ciferri M, Darian-Smith C. Adult neurogenesis in primate and rodent spinal cord: comparing a cervical dorsal rhizotomy with a dorsal column transection. European Journal of Neuroscience. 2007;26(10):2777&#x2013;2794.</Citation><ArticleIdList><ArticleId IdType="pubmed">18001275</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters S, Zitzelsperger E, Kuespert S, et al. The TGF-&#x3b2; System As a Potential Pathogenic Player in Disease Modulation of Amyotrophic Lateral Sclerosis. Front. Neurol. 2017;8:181&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5736544</ArticleId><ArticleId IdType="pubmed">29326641</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorrells SF, Sapolsky RM. An inflammatory review of glucocorticoid actions in the CNS. Brain Behav. Immun. 2007;21(3):259&#x2013;272.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1997278</ArticleId><ArticleId IdType="pubmed">17194565</ArticleId></ArticleIdList></Reference><Reference><Citation>Boldrini M, Fulmore CA, Tartt AN, et al. Human Hippocampal Neurogenesis Persists throughout Aging. Stem Cell. 2018;22(4):589&#x2013;599.e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5957089</ArticleId><ArticleId IdType="pubmed">29625071</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder JS. Recalibrating the Relevance of Adult Neurogenesis. Trends in Neurosciences. 1&#x2013;15 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30686490</ArticleId></ArticleIdList></Reference><Reference><Citation>Moustakas A, Miyazawa K, editors. TGF-&#x3b2; in Human Disease.</Citation></Reference><Reference><Citation>Aigner L, Bogdahn U. TGF-beta in neural stem cells and in tumors of the central nervous system. Cell and tissue research. 2008;331(1):225&#x2013;241.</Citation><ArticleIdList><ArticleId IdType="pubmed">17710437</ArticleId></ArticleIdList></Reference><Reference><Citation>Wachs F-P, Winner B, Couillard-Despres S, et al. Transforming growth factor-beta1 is a negative modulator of adult neurogenesis. J. Neuropathol. Exp. Neurol. 2006;65(4):358&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pubmed">16691117</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckwalter MS, Yamane M, Coleman BS, et al. Chronically increased transforming growth factor-beta1 strongly inhibits hippocampal neurogenesis in aged mice. The American Journal of Pathology. 2006;169(1):154&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1698757</ArticleId><ArticleId IdType="pubmed">16816369</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckwalter MS, Wyss-Coray T. Modelling neuroinflammatory phenotypes in vivo. J Neuroinflammation. 2004;1(1):10&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC500895</ArticleId><ArticleId IdType="pubmed">15285805</ArticleId></ArticleIdList></Reference><Reference><Citation>Kubiczkova L, Sedlarikova L, Hajek R, Sevcikova S. TGF-&#x3b2; - an excellent servant but a bad master. J Transl Med. 2012;10(1):183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3494542</ArticleId><ArticleId IdType="pubmed">22943793</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YE. Non-Smad pathways in TGF-&#x3b2; signaling. Cell Res. 2009;19(1):128&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2635127</ArticleId><ArticleId IdType="pubmed">19114990</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikushima H, Miyazono K. TGF-&#x3b2; signal transduction spreading to a wider field: a broad variety of mechanisms for context-dependent effects of TGF-&#x3b2;. Cell and tissue research. 2011;347(1):37&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">21618142</ArticleId></ArticleIdList></Reference><Reference><Citation>Strasen J, Sarma U, Jentsch M, et al. Cell-specific responses to the cytokine TGF&#x3b2; are determined by variability in protein levels. Mol Syst Biol. 2018;14(1):e7733&#x2013;e7817.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5787704</ArticleId><ArticleId IdType="pubmed">29371237</ArticleId></ArticleIdList></Reference><Reference><Citation>Zi Z, Chapnick DA, Liu X. Dynamics of TGF-&#xce;2/Smad signaling. FEBS Letters. 2012;586(14):1921&#x2013;1928.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4127320</ArticleId><ArticleId IdType="pubmed">22710166</ArticleId></ArticleIdList></Reference><Reference><Citation>Blank U, Karlsson S. TGF-&#x3b2; signaling in the control of hematopoietic stem cells. Blood. 2015;125(23):3542&#x2013;3550.</Citation><ArticleIdList><ArticleId IdType="pubmed">25833962</ArticleId></ArticleIdList></Reference><Reference><Citation>Cua DJ, Kastelein RA. TGF-[beta], a &#x201c;double agent&#x201d; in the immune pathology war. Nat Immunol. 2006;7(6):557&#x2013;560.</Citation><ArticleIdList><ArticleId IdType="pubmed">16715066</ArticleId></ArticleIdList></Reference><Reference><Citation>Galbiati M, Crippa V, Rusmini P, et al. Multiple Roles of Transforming Growth Factor Beta in Amyotrophic Lateral Sclerosis. International Journal of Molecular Sciences 2012, Vol. 13, Pages 8219&#x2013;8258. 21(12), 4291 (2020).</Citation></Reference><Reference><Citation>Kuespert S, Heydn R, Peters S, et al. Antisense Oligonucleotide in LNA-Gapmer Design Targeting TGFBR2 &#x2013; A Key Single Gene Target for Safe and Effective Inhibition of TGF&#x3b2; Signaling. International Journal of Molecular Sciences 2012, Vol. 13, Pages 8219&#x2013;8258. 21(6), 1952&#x2013;25 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7139664</ArticleId><ArticleId IdType="pubmed">32178467</ArticleId></ArticleIdList></Reference><Reference><Citation>Hua Y, Sahashi K, Hung G, et al. Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev. 2010;24(15):1634&#x2013;1644.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2912561</ArticleId><ArticleId IdType="pubmed">20624852</ArticleId></ArticleIdList></Reference><Reference><Citation>Md DRSF, Md CAC, Md JV, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. The Lancet. 2016;388(10063):3017&#x2013;3026.</Citation><ArticleIdList><ArticleId IdType="pubmed">27939059</ArticleId></ArticleIdList></Reference><Reference><Citation>Passini MA, Bu J, Richards AM, et al. Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci Transl Med. 2011;3(72):72ra18&#x2013;72ra18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3140425</ArticleId><ArticleId IdType="pubmed">21368223</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiriboga CA, Swoboda KJ, Darras BT, et al. Results from a phase 1 study of nusinersen (ISIS-SMN Rx) in children with spinal muscular atrophy. Neurology. 2016;86(10):890&#x2013;897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4782111</ArticleId><ArticleId IdType="pubmed">26865511</ArticleId></ArticleIdList></Reference><Reference><Citation>Dias JM, Alekseenko Z, Applequist JM, Ericson J. Tgf&amp;beta; Signaling Regulates Temporal Neurogenesis and Potency of Neural Stem Cells in the CNS. Neuron. 2014;84(5):927&#x2013;939.</Citation><ArticleIdList><ArticleId IdType="pubmed">25467979</ArticleId></ArticleIdList></Reference><Reference><Citation>Watabe T, Miyazono K. Roles of TGF-&#x3b2; family signaling in stem cell renewal and differentiation. Cell Res. 2009;19(1):103&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pubmed">19114993</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandasamy M, Couillard-Despres S, Raber KA, et al. Stem cell quiescence in the hippocampal neurogenic niche is associated with elevated transforming growth factor-beta signaling in an animal model of Huntington disease. J. Neuropathol. Exp. Neurol. 2010;69(7):717&#x2013;728.</Citation><ArticleIdList><ArticleId IdType="pubmed">20535034</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandasamy M, Lehner B, Kraus S, et al. TGF-beta signalling in the adult neurogenic niche promotes stem cell quiescence as well as generation of new neurons. J. Cell. Mol. Med. 2014;18(7):1444&#x2013;1459.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4124027</ArticleId><ArticleId IdType="pubmed">24779367</ArticleId></ArticleIdList></Reference><Reference><Citation>Genin EC, Caron N, Vandenbosch R, Nguyen L, Malgrange B. Concise Review: Forkhead Pathway in the Control of Adult Neurogenesis. Stem Cells. 2014;32(6):1398&#x2013;1407.</Citation><ArticleIdList><ArticleId IdType="pubmed">24510844</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer M, Berger I, Winter J, Jurek B. Oxytocin alters the morphology of hypothalamic neurons via the transcription factor myocyte enhancer factor 2A (MEF-2A) Molecular and cellular endocrinology. 2018;477:156&#x2013;162.</Citation><ArticleIdList><ArticleId IdType="pubmed">29928931</ArticleId></ArticleIdList></Reference><Reference><Citation>Flavell SW, Kim T-K, Gray JM, et al. Genome-wide analysis of MEF2 transcriptional program reveals synaptic target genes and neuronal activity-dependent polyadenylation site selection. Neuron. 2008;60(6):1022&#x2013;1038.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2630178</ArticleId><ArticleId IdType="pubmed">19109909</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandasamy M, Rosskopf M, Wagner K, et al. Reduction in Subventricular Zone-Derived Olfactory Bulb Neurogenesis in a Rat Model of Huntington's Disease Is Accompanied by Striatal Invasion of Neuroblasts. PLoS ONE. 2015;10(2):e0116069.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4342015</ArticleId><ArticleId IdType="pubmed">25719447</ArticleId></ArticleIdList></Reference><Reference><Citation>nez EPM-JX, a MF-GX, Terreros-Roncal J, et al. Adult hippocampal neurogenesis is abundant in neurologically healthy subjects and drops sharply in patients with Alzheimer&#x2019;s disease. Nature Publishing Group. 1&#x2013;28 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30911133</ArticleId></ArticleIdList></Reference><Reference><Citation>Gal&#xe1;n L, G&#xf3;mez-Pinedo U, Guerrero A, Garc&#xed;a-Verdugo JM, Mat&#xed;as-Guiu J. Amyotrophic lateral sclerosis modifies progenitor neural proliferation in adult classic neurogenic brain niches. BMC Neurol. 2017;17(1):1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5585932</ArticleId><ArticleId IdType="pubmed">28874134</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-Pinedo U. Notch Signalling in the Hippocampus of Patients With Motor Neuron Disease. fnins-13&#x2013;00302.tex. 1&#x2013;13 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6460507</ArticleId><ArticleId IdType="pubmed">31024234</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandasamy M, Reilmann R, Winkler J, Bogdahn U, Aigner L. Transforming Growth Factor-Beta Signaling in the Neural Stem Cell Niche: A Therapeutic Target for Huntington's Disease. Neurology Research International. 2011;2011(2):1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3134994</ArticleId><ArticleId IdType="pubmed">21766020</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandasamy M, Anusuyadevi M, Aigner KM, et al. TGF-&#x3b2; Signaling: A Therapeutic Target to Reinstate Regenerative Plasticity in Vascular Dementia? Aging and Disease. (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7390515</ArticleId><ArticleId IdType="pubmed">32765949</ArticleId></ArticleIdList></Reference><Reference><Citation>Endo F, Komine O, Fujimori-Tonou N, et al. Astrocyte-derived TGF-&#x3b2;1 accelerates disease progression in ALS mice by interfering with the neuroprotective functions of microglia and T cells. Cell Reports. 2015;11(4):592&#x2013;604.</Citation><ArticleIdList><ArticleId IdType="pubmed">25892237</ArticleId></ArticleIdList></Reference><Reference><Citation>Endo F, Yamanaka K. Astrocytic TGF-&#x3b2;1: detrimental factor in ALS. Oncotarget. 2015;6(18):15728&#x2013;15729.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4599223</ArticleId><ArticleId IdType="pubmed">26164079</ArticleId></ArticleIdList></Reference><Reference><Citation>ShenLijiang, HungGene AE, et al. Effects of Repeated Complement Activation Associated with Chronic Treatment of Cynomolgus Monkeys with 2&#x2032;-O-Methoxyethyl Modified Antisense Oligonucleotide. Nucleic Acid Therapeutics. 2016;26(4):236&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pubmed">27140858</ArticleId></ArticleIdList></Reference><Reference><Citation>Lerman BJ, Hoffman EP, Sutherland ML, et al. Deletion of galectin-3 exacerbates microglial activation and accelerates disease progression and demise in a SOD1(G93A) mouse model of amyotrophic lateral sclerosis. Brain Behav. 2012;2(5):563&#x2013;575.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3489809</ArticleId><ArticleId IdType="pubmed">23139902</ArticleId></ArticleIdList></Reference><Reference><Citation>Gautier L, Cope L, Bolstad BM, Irizarry RA. affy&#x2013;analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 2004;20(3):307&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pubmed">14960456</ArticleId></ArticleIdList></Reference><Reference><Citation>Durinck S, Spellman PT, Birney E, Huber W. Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt. Nat Protoc. 2009;4(8):1184&#x2013;1191.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3159387</ArticleId><ArticleId IdType="pubmed">19617889</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic acids research. 2015;43(7):e47&#x2013;e47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4402510</ArticleId><ArticleId IdType="pubmed">25605792</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabin SJ, Kim JMH, Baughn M, et al. Sporadic ALS has compartment-specific aberrant exon splicing and altered cell-matrix adhesion biology. Human Molecular Genetics. 2010;19(2):313&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2796893</ArticleId><ArticleId IdType="pubmed">19864493</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>